Rheumatoid arthritis drug anakinra in small study to treat COVID-19
A small observational study reported in Lancet Rheumatology used the rheumatoid arthritis drug anakinra, a recombinant interleukin-1 receptor antagonist, for the treatment of COVID-19. 
The study was conducted in Milan in 29 patients hospitalised with COVID-19 (median age 62, many with comorbidities) who received daily high-dose intravenous infusions of anakinra at 10 mg/kg bodyweight for 21 days in addition to standard of care standard care (non-invasive ventilation (CPAP), hydroxychloroquine, and lopinavir/r). Results were compared to a non-randomised control group of 16 people who only received standard of care.
Respiratory improvements and reduced signs of cytokine activity including reduced C-reactive protein was reported in 72% (21/29) of patients. Survival was 90% (26 out of 29). Five of 29 patients (17%) needed mechanical ventilation.
This compared to persistent or recurrent increases in C-reactive protein in most of the control group. Respiratory function improved for half of the patients (8 patients, 50%), and 56% (nine of 16) survived. One patient received mechanical ventilation (6%).
The authors commented that anakinra has a stronger safety record compared with other cytokine-blocking agents and a shorter half-life, making it suitable for critically ill patients, but that their findings needed to be tested in larger randomised studies.
The study is also part of the prospective 1000-person COVID-19 Biobank study looking for predictors of response and outcomes to COVID-19. 
- Cavalli G et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatology DOI: 10.1016/S2665-9913(20)30127-2. (7 May 2020).
- clinicaltrials.gov. COVID-19 Patients characterization, biobank, treatment response and outcome predictor (COVID-BioB).